摘要
目的观察沙利度胺联合TACE治疗中晚期肝癌的临床疗效及其影响。方法39例被确诊为中晚期肝癌,随机双盲服用沙利度胺或纤维素片100mg口服,早晚各1次,两周后200mg口服,早晚各1次,每两周加量200mg,至患者不能耐受,并联合TACE治疗,观察患者临床疗效及临床不良反应。结果治疗组(服用沙利度胺)PFS为(5.40±5.58)月,OS为(8.82±7.00)月,AFP降低指数为(1.50±0.86),对照组(服用纤维素片)分别为(4.23±5.59)月,(8.19±6.60)月,(1.43±1.03),与治疗组对应比较差异无统计学意义(P>0.05)。结论沙利度胺联合TACE治疗晚期肝癌较单用TACE延长PFS、OS不明显。
Objective To observe the clinical efficacy and effect of Thalidomide combined with transcatheter arterial chemoembolization in treatment of advanced primary carcinoma of liver.Methods Thirty-nine patients were randomly divided into treatment group and control group.The patients of treatment group received Thalidomide 100mg bis in die,200mg bis in die after two weeks,and then added 200mg at an interval of every forth night and combined with TACE.The patients of control group were treated with TACE alone to observe curative effect and clinical adverse effect.Results The progress free survival of the treatment group was （5.40±5.58） months,the progress free survival of the control group was （4.23±5.59） months,there was no significant difference between the two groups （P0.05）.The overall survival of the treatment group was （8.82±7.00） months,the overall survival of the control group was （8.19±6.60） months,there was no significant difference between the two groups （P0.05）.The alpha-fetoprotein decreasing rate of the treatment group was （1.50±0.86）.The alpha-fetoprotein decreasing rate of the control group was （1.43±1.03）.There was no significant difference between the two groups （P0.05）.Conclusion Compared with TACE alone,the combination of TACE and thalidomide isn＇t conspicuous to prolong the progress free survival and the overall survival of PLA patients.
出处
《安徽医学》
2009年第11期1270-1272,共3页
Anhui Medical Journal
基金
合肥市重点科研基金资助项目[编号(2007015)]
关键词
原发性肝癌
沙利度胺
肝动脉栓塞化疗
Primary carcinoma of liver
Thalidomide
Transcatheter arterial chemoembolization
